tirzepatide and cardiovascular outcomes Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Randomized clinical trials with cardiovascular

GLP-1 agonists, like semaglutide, are medications that stimulate the GLP-1 pathway and are used to treat conditions like type 2 diabetes and obesity by reducing appetite and promoting weight loss 3

While side effects occur from taking such drugs, the potential benefits outweigh any risks if taken as prescribed by a health care professional

Suitable for those who prefer a once-weekly treatment instead of daily medication

In a previous study, we demonstrated that patients using the recommended weight loss dose of semaglutide for 60 weeks achieved weight loss of 8-11% of their initial body weight

Research in this area is preliminary, and is still ongoing